COMP <GO>
CALC vs GTBP // RSI-14 & 200D SMA MOMENTUM
CalciMedica Inc. (NASDAQ) VS. GT Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: CALC 2
— GTBP 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CALC
LAST: $1.75 (+5.42%) • MKT CAP: $11.9M
rsi-technicals
49.1
LAST: $5.60 (+1.63%) • MKT CAP: $11.5M
rsi-technicals
41.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CALC VS. GTBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CALC | GTBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.98% | -1.98 | GTBP | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 49.1 | 41.4 | +7.73 | CALC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.9M | $11.5M | $407.6K | CALC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CALC REV | GTBP REV | CALC GROSS % | GTBP GROSS % | CALC FCF | GTBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$21.2M | -$12.9M |
| FY 2024 | $0 | $0 | — | — | -$21.2M | -$12.9M |
| FY 2023 | $0 | $0 | — | — | -$25.7M | -$8.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CALC // BETA —
GTBP // BETA —